MAR 8-9 PCAC

Results Wire: US FDA Pharmacy Compounding Advisory Committee Votes on Nominees for the “Bulk Substances Allowed” and “Demonstrably Difficult” Lists – MAR 8-9, 2016 (PCAC)

On Tuesday and Wednesday, March 8-9, 2016, the Pharmacy Compounding Advisory Committee (PCAC) agreed with the FDA to exclude six bulk drug substances that were nominated for inclusion on the list of bulk substances to allow in drug compounding. In addition, the Committee agreed with the FDA to include two drug product categories nominated for inclusion on the list of drug products that present demonstrable difficulties for compounding.

See the SAC Tracker report